Medicare Advantage Enrollment Surge: Navigating the New Lead Landscape

Medicare Advantage now covers more than 35 million Americans. SNPs are driving 83% of new growth. And the lead infrastructure built for a simpler market can’t keep up.

The Milestone Nobody Was Ready For

As of February 2026, more than 35 million Americans are enrolled in Medicare Advantage plans—an increase of 1.1 million over the prior year. MA now covers 54% of all eligible Medicare beneficiaries, up from just 19% in 2007. The Congressional Budget Office projects that share will reach 64% by 2034.

Source: KFF – Medicare Advantage Enrollment Grew by About 1 Million People, Mainly Due to Special Needs Plans (February 2026)

These are milestone numbers. But beneath the headline, the composition of that growth has shifted in a way that fundamentally changes what lead distribution must deliver. MA enrollment growth has slowed to 3% year-over-year—the lowest rate in two decades and well below the 9% annual average from 2007 to 2024. Individual plan enrollment grew by just 224,000 members. Employer-sponsored group plans actually declined.

Where did the growth come from? Special Needs Plans. SNPs accounted for 83% of all MA enrollment gains in 2026. More than 8 million beneficiaries are now enrolled in SNPs, up nearly 900,000 from a year earlier. Their share of total MA enrollment has risen from 13% in 2018 to 23% in 2026.

Source: KFF – Medicare Advantage in 2025: Enrollment Update and Key Trends (July 2025)

The Supply Chain Wasn’t Built for This

The Medicare lead generation infrastructure was designed for a simpler market: one product (standard MA), one enrollment window (AEP), one buyer persona (the healthy senior choosing between MA and traditional Medicare). The supply chain optimized for volume because volume was the only variable that mattered.

That market no longer exists. Today’s MA landscape includes standard Medicare Advantage, D-SNPs for dual-eligible beneficiaries, C-SNPs for individuals with specific chronic conditions, and I-SNPs for institutionalized populations. Each product requires a fundamentally different member profile. A lead that is ideal for a standard MA plan may be entirely wrong for a D-SNP. A prospect who qualifies for a C-SNP may be invisible to a lead form that doesn’t capture chronic condition indicators.

Meanwhile, the market itself is fragmenting. KFF reports that 2.6 million enrollees in individual MA plans faced plan terminations heading into 2026—double the number from the prior year. The total number of available MA plans fell 9%, and three of the five largest MA insurers, including market leader UnitedHealth Group, experienced overall enrollment declines. Smaller, SNP-focused entrants are gaining share rapidly.

Sources: KFF – Medicare Advantage 2026 Spotlight: Plan Offerings (January 2026) | Rise Health – MA Enrollment Rises, Driven Largely by SNPs (2026)

The Regulatory Crosscurrents

Compounding the distribution challenge is a regulatory environment that is pulling in two directions simultaneously. The CY2026 final rule, released in April 2025 under new CMS Administrator Dr. Mehmet Oz, finalized certain beneficiary protections—including requirements for plans to honor prior authorization decisions and improvements to D-SNP enrollee experience—but deferred action on several Biden-era proposals addressing internal coverage criteria, AI guardrails, and expanded health equity analyses.

Source: CMS – CY2026 Final Rule (Federal Register, April 15, 2025)

Then in November 2025, CMS proposed a new rule that would relax several marketing oversight measures, including removing time and manner restrictions on broker marketing at educational events and reducing call recording retention requirements. The comment period closed in January 2026.

Source: Morgan Lewis – Medicare Advantage Agent & Broker Agreements: 2025 in Review (February 2026)

For FMOs and agencies, the net effect is uncertainty. Some compliance requirements are tightening. Others may loosen. The market is growing but diversifying. And the lead supply chain that served a simpler era isn’t equipped to route the right lead to the right product in a market that now demands product-specific matching at scale.

Sequential Intelligence as a Supply Chain Stabilizer

This is the environment RiskLync’s Sequential Intelligence Pipeline was designed for—a market where knowing the product fit of a lead is as important as knowing whether it will convert at all.

ZipLync (Pre-Purchase): Before an agency buys a lead, ZipLync’s socioeconomic, behavioral and geographic model scores conversion probability across 32,000+ ZIP codes. But in a diversifying market, geographic scoring does more than predict general conversion—it identifies the product density of a geography. ZIP codes with high concentrations of dual-eligible beneficiaries signal D-SNP opportunity. ZIPs with elevated chronic condition prevalence signal C-SNP potential. The pre-purchase score isn’t just a quality filter; it’s a product-mix signal.

ProLyncMA (Post-Purchase): Once a lead is acquired, ProLyncMA applies Behavioral Scoring using 3,000+ socioeconomic and behavioral attributes to score for general Medicare Advantage fit. Leads that score well proceed to the appropriate agent queue.

ProLyncC (Post-Purchase): Leads flagged with high probability of having a chronic condition indicators are routed to the ProLyncC model, which evaluates C-SNP qualification. In a market where C-SNP enrollment grew 71% in a single year, this product-specific routing is no longer optional—it’s where the growth is.

Source: KFF – Medicare Advantage in 2025: C-SNP Enrollment Data (July 2025)

ProLyncD (Post-Purchase): Leads with income and benefits profiles indicating Medicaid-Medicare dual eligibility probability are scored by ProLyncD for D-SNP fit. With D-SNPs representing the largest segment of the SNP market and 83% of all MA enrollment growth, this is the model that addresses the single biggest enrollment trend in Medicare today.

In RiskLync’s retrospective AEP 2026 Medicare study, this sequential approach delivered a 106% enrollment lift on the same budget—not by finding more leads, but by matching each lead to the product where it had the highest probability of converting.

The Distribution Question for 2026 and Beyond

Medicare Advantage is no longer a single-product market with a simple distribution problem. It is a multi-product ecosystem where 35 million beneficiaries are distributed across standard MA, D-SNPs, C-SNPs, I-SNPs, and employer group plans—each with different eligibility criteria, benefit structures, and regulatory requirements. The organizations that win in this market won’t be those that buy the most leads. They’ll be those that can answer, for every lead, two questions in sequence: Is this lead worth buying? And which product does it belong to?

ZipLync answers the first. ProLync—in its MA, C, and D variants—answers the second. Together, they transform lead acquisition from a volume game into a precision operation built for the market Medicare has actually become.

Your market isn’t one product anymore. Your lead scoring shouldn’t be, either. Request a AEP 2026 retroactive study and see where your growth (or bleed) was concentrated - before your next lead purchase.